Diffuse large B-cell lymphoma: Clinical characterization and prognosis of waldeyer ring versus lymph node presentation

Cancer

Volumn 115, Issue 21, 2009, Pages 4980-4989

  Qi, Shu Nan ^a   Li, Ye Xiong ^a   Wang, Hua ^a   Wang, Wei Hu ^a   Jin, Jing ^a   Song, Yong Wen ^a   Wang, Shu Lian ^a   Liu, Yue Ping ^a   Zhou, Li Qiang ^a   Yu, Zi Hao ^a  

^a CANCER HOSPITAL   (China)

Author keywords

Diffuse large B cell lymphoma; Lymph node group; Prognosis; Waldeyer ring

Indexed keywords

BETA 2 MICROGLOBULIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; LACTATE DEHYDROGENASE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; LYMPH NODE; LYMPH NODE DIFFUSE LARGE B CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SENESCENCE; SYMPTOM; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR LOCALIZATION; TUMOR VOLUME; WALDEYER RING; WALDEYER RING DIFFUSE LARGE B CELL LYMPHOMA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LYMPH NODES; LYMPHOID TISSUE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PROGNOSIS; TONSILLAR NEOPLASMS; TREATMENT OUTCOME;

EID: 70350516566     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24557     Document Type: Article

References (32)

1. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol. 1998;16:2780-2795.
2. The Non-Hodgkin's Lymphoma Classification Project.A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood. 1997;89:3909-3918.
3. Harris NL, Jaffe ES, Stein H, et al. A revised European- American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361-1392. (Pubitemid 24273002)
4. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology. 2000;36:69-86.
5. Moller MB, Pedersen NT, Christensen BE. Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation - a population-based study of 1575 cases. Br J Haematol. 2004;124:151-159.
6. Lopez-Guillermo A, Colomo L, Jimenez M, et al. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol. 2005;23:2797-2804. (Pubitemid 46179470)
7. d'Amore F, Christensen BE, Brincker H, et al. Clinicopathological features and prognostic factors in extranodal non-Hodgkin lymphomas. Danish LYFO Study Group. Eur J Cancer. 1991;27:1201-1208.
8. Krol AD, Le Cessie S, Snijder S, et al. Waldeyer's ring lymphomas: a clinical study from the Comprehensive Cancer Center West population based NHL Registry. Leuk Lymphoma. 2001;42:1005-1013. (Pubitemid 32827522)
9. Ezzat AA, Ibrahim EM, El Weshi AN, et al. Localized non- Hodgkin's lymphoma of Waldeyer's ring: clinical features, management, and prognosis of 130 adult patients. Head Neck. 2001;23:547-558.
10. Li YX, Gao YH, Yuan ZY, et al. Prognostic significance of International Prognostic Index in non-Hodgkin's lymphoma of Waldeyer's ring. Chin J Radiat Oncol. 2002; 11:105-110.
11. Chuang SS, Lin CN, Li CY. Malignant lymphoma in southern Taiwan according to the revised European-American classification of lymphoid neoplasms. Cancer. 2000;89: 1586-1592.
12. Krol AD, le Cessie S, Snijder S, et al. Primary extranodal non-Hodgkin's lymphoma (NHL): the impact of alternative definitions tested in the Comprehensive Cancer Centre West population-based NHL Registry. Ann Oncol. 2003;14: 131-139.
13. Laskar S, Bahl G, Muckaden MA, et al. Primary diffuse large B-cell lymphoma of the tonsil: is a higher radiotherapy dose required? Cancer. 2007;110:816-823.
14. Li YX, Yao B, Jin J, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol. 2006;24:181-189.
15. Cheung MMC, Chan JK, Lau WH, et al. Primary non- Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol. 1998;16:70-77.
16. Li YX, Coucke PA, Li JY, et al. Primary non-Hodgkin's lymphoma of the nasal cavity: prognostic significance of paranasal extension and the role of radiotherapy and chemotherapy. Cancer. 1998;83:449-456.
17. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275-282.
18. Shipp MA, Harrington DP, Anderson JR, et al. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987-994.
19. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25: 579-586. (Pubitemid 350002966)
20. Tan LH. Lymphomas involving Waldeyer's ring: placement, paradigms, peculiarities, pitfalls, patterns and postulates. Ann Acad Med Singapore. 2004;33(suppl 4):15-26.
21. Barrans SL, Carter I, Owen RG, et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patients risk stratification in diffuse large B-cell lymphoma. Blood. 2002;99:1136-1143. (Pubitemid 34547064)
22. Li YX, Fang H, Liu QF, et al. Clinical features and treatment outcome of nasal-type NK/T-cell lymphoma of Waldeyer ring. Blood. 2008;112:3057-3064.
23. Layland MK, Sessions DG, Lenox J. The influence of lymph node metastasis in the treatment of squamous cell carcinoma of the oral cavity, oropharynx, larynx, and hypopharynx: N0 versus N+. Laryngoscope. 2005;115:629-639. (Pubitemid 40530012)
24. Yi JL, Gao L, Huang XD, et al. Nasopharyngeal carcinoma treated by radical radiotherapy alone: ten year experience of a single institution. Int J Radiat Oncol Biol Phys. 2006;65: 161-168.
25. Armitage JO. How I treat patients with diffuse large B-cell lymphoma. Blood. 2007;110:29-36. (Pubitemid 47026815)
26. Aviles A, Delgado S, Ruiz H, et al. Treatment of non- Hodgkin's lymphoma of Waldeyer's ring: radiotherapy versus chemotherapy versus combined therapy. Eur J Cancer B Oral Oncol. 1996;32B:19-23.
27. Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared to chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med. 1998;339:21-26. (Pubitemid 28304493)
28. Horning SH, Weller E, Kim KM, et al. Chemotherapy with or without radiotherapy in limited stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group Study 1484. J Clin Oncol. 2004;22:3032-3038. (Pubitemid 41103714)
29. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med. 2002;346:235-242.
30. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large B-cell lymphoma: a randomized controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379-391.
31. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus 8 cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105-116.
32. Malumbres R, Chen J, Tibshirani R, et al. Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Blood. 2008;111: 5509-5514.